StemCell Therapy

Robert W. Baird began coverage on shares of Vir Biotechnology (NYSE:VIR) in a report released on Wednesday, November 13th, The Fly reports. The firm issued a neutral rating on the stock.

Other analysts have also issued reports about the company. Cowen assumed coverage on Vir Biotechnology in a report on Tuesday, November 5th. They set an outperform rating on the stock. Goldman Sachs Group began coverage on Vir Biotechnology in a research note on Tuesday, November 5th. They issued a buy rating and a $37.00 price objective on the stock. Barclays began coverage on Vir Biotechnology in a research note on Tuesday, November 5th. They issued an overweight rating and a $25.00 price objective on the stock. Finally, JPMorgan Chase & Co. began coverage on Vir Biotechnology in a research note on Tuesday, November 5th. They issued an overweight rating and a $25.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Vir Biotechnology currently has an average rating of Buy and an average target price of $29.00.

VIR stock traded up $0.07 during trading hours on Wednesday, hitting $11.90. 101,085 shares of the stock were exchanged, compared to its average volume of 164,664. Vir Biotechnology has a 12 month low of $11.65 and a 12 month high of $16.50.

Vir Biotechnology (NYSE:VIR) last posted its quarterly earnings data on Tuesday, November 19th. The company reported ($4.60) earnings per share for the quarter, missing the consensus estimate of ($3.71) by ($0.89). The business had revenue of $1.40 million during the quarter.

In other Vir Biotechnology news, major shareholder Endurance (Cayman) Ltd Svf bought 950,000 shares of the companys stock in a transaction on Wednesday, October 16th. The stock was acquired at an average price of $14.22 per share, for a total transaction of $13,509,000.00. Also, insider Abu Dhabi Investment Authority bought 1,000,000 shares of the companys stock in a transaction on Wednesday, October 16th. The shares were acquired at an average price of $14.41 per share, with a total value of $14,410,000.00.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis.

Further Reading: What are the qualifications of a portfolio manager?

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

See the original post:
Vir Biotechnology (NYSE:VIR) Coverage Initiated by Analysts at Robert W. Baird - TechNewsObserver

This entry was posted on November 28, 2019 at 4:46 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |